36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO
Copyright policy )36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO
AbstractEndovascular ultrasound renal denervation (uRDN) reduced blood pressure (BP) compared to sham at 2 months in patients with resistant hypertension in the multicenter, blinded, randomized, sham-controlled RADIANCE-HTN TRIO trial. This analysis evaluates longer-term outcomes of patients randomized to uRDN. Patients with resistant hypertension to a 3-drug combination pill were randomized to uRDN (n = 69) or sham (n = 67). From 2-5 months, patients followed a standardized anti-hypertensive medication (AHM) titration protocol. At 6 months, patients were unblinded and received AHM per standard of care. In the uRDN group, 71% (49/69) completed 36-month follow-up. Screening office BP was 159/103 on 3.9 AHM. Baseline office BP on the single-pill combination was 153/99 mmHg. At 36 months, office BP changed by −14.5 ± 26.1/−9.0 ± 14.8 mmHg from screening (p < 0.001 for both) and −8.0 ± 24.5/−5.0 ± 14.6 mmHg from baseline (p = 0.007; p = 0.022) on 3.7 AHM. The efficacy of uRDN was durable to 36 months in patients with resistant hypertension with no safety concerns.
- Hôpital de la Croix-Rousse France
- Düsseldorf University Hospital Germany
- University of Pennsylvania United States
- Assistance Publique -Hopitaux De Paris France
- University Hospitals Sussex NHS Foundation Trust United Kingdom
Male, Adult, hypertension, ultrasound, 610, blood pressure, Blood Pressure, Middle Aged, Brief Communication, Kidney, Treatment Outcome, Hypertension, Female [MeSH] ; Aged [MeSH] ; Adult [MeSH] ; Humans [MeSH] ; Hypertension/surgery [MeSH] ; Blood Pressure/drug effects [MeSH] ; Treatment Outcome [MeSH] ; Middle Aged [MeSH] ; ultrasound ; Brief Communication ; Kidney/diagnostic imaging [MeSH] ; Sympathectomy/methods [MeSH] ; Hypertension/drug therapy [MeSH] ; Male [MeSH] ; Kidney/innervation [MeSH] ; blood pressure ; Drug Therapy, Combination [MeSH] ; brief-communication ; renal denervation ; Antihypertensive Agents/therapeutic use [MeSH] ; Hypertension, Humans, Female, Drug Therapy, Combination, Sympathectomy, renal denervation, Antihypertensive Agents, Aged
Male, Adult, hypertension, ultrasound, 610, blood pressure, Blood Pressure, Middle Aged, Brief Communication, Kidney, Treatment Outcome, Hypertension, Female [MeSH] ; Aged [MeSH] ; Adult [MeSH] ; Humans [MeSH] ; Hypertension/surgery [MeSH] ; Blood Pressure/drug effects [MeSH] ; Treatment Outcome [MeSH] ; Middle Aged [MeSH] ; ultrasound ; Brief Communication ; Kidney/diagnostic imaging [MeSH] ; Sympathectomy/methods [MeSH] ; Hypertension/drug therapy [MeSH] ; Male [MeSH] ; Kidney/innervation [MeSH] ; blood pressure ; Drug Therapy, Combination [MeSH] ; brief-communication ; renal denervation ; Antihypertensive Agents/therapeutic use [MeSH] ; Hypertension, Humans, Female, Drug Therapy, Combination, Sympathectomy, renal denervation, Antihypertensive Agents, Aged
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).10 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!